3-Methyl-6-i-propyl-s-tetrazin | 34753-06-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四嗪
• 英文名称: 3-Methyl-6-i-propyl-s-tetrazin
• 英文别名: 3-isopropyl-6-methyl-[1,2,4,5]tetrazine；3-Methyl-6-propan-2-yl-1,2,4,5-tetrazine
• CAS: 34753-06-5
• 化学式: C₆H₁₀N₄
• 分子量: 138.172
• InChiKey: LEWLJUJLDRGYQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  51.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Substituted Imidazo[2,1-b]thiazole Compounds and Uses Thereof
  申请人：KUEHNERT Sven

  公开号：US20090005399A1

  公开（公告）日：2009-01-01

  Substituted imidazo[2,1-b]thiazole compounds corresponding to formula I, a method for producing them, pharmaceutical compositions containing them, and the use thereof for regularing mGluR5 receptors, or for treating or inhibiting disorders or disease states at least partially mediated by mGluR5 receptor such as pain, anxiety attacks, drug or alcohol dependency, and others.

  替代imidazo[2,1-b]噻唑化合物对应于公式I，一种生产它们的方法，含有它们的药物组合物，以及将其用于调节mGluR5受体，或用于治疗或抑制至少部分由mGluR5受体介导的疾病或疾病状态，如疼痛、焦虑发作、药物或酒精依赖等。
• [EN] PYRIDAZINE COMPOUNDS AS JAK INHIBITORS<br/>[FR] COMPOSÉS DE PYRIDAZINE EN TANT QU'INHIBITEURS DE JAK
  申请人：PORTOLA PHARM INC

  公开号：WO2015123453A1

  公开（公告）日：2015-08-20

  In one aspect, the invention provides a compound according to formula I, as well as tautomers, pharmaceutically acceptable salts, and hydrates thereof. Pharmaceutical compositions, methods of inhibiting Janus kinases (JAKs), and methods for treating a condition or disorder mediated at least in part by JAK kinase activity are also described.

  在一个方面，该发明提供了一个符合式I的化合物，以及其互变异构体、药用盐和水合物。还描述了药物组合物、抑制JAK（Janus激酶）的方法，以及治疗至少部分由JAK激酶活性介导的情况或疾病的方法。
• COMPOUNDS AND METHODS FOR SELECTIVE C-TERMINAL LABELING
  申请人：Quantum-Si Incorporated

  公开号：US20210221839A1

  公开（公告）日：2021-07-22

  The present disclosure relates to compounds and methods for selective C-terminal functionalization of peptides. In certain embodiments, the compounds have improved water-solubility, and are suitable for use in connection with peptide sequencing methodologies.

  本公开涉及化合物和方法，用于选择性地对肽的C-末端进行功能化。在某些实施例中，这些化合物具有改善的水溶性，并适用于与肽测序方法相关的应用。
• MULTIPLE CYCLOADDITION REACTIONS FOR LABELING OF MOLECULES
  申请人：EUROPEAN MOLECULAR BIOLOGY LABORATORY

  公开号：US20160340297A1

  公开（公告）日：2016-11-24

  The present invention relates to methods for linking tetrazines with dienophiles to establish at least two linkages by sequentially performing at least two cycloaddition reactions. The methods in particular allow establishing multi-labeling strategies. In particular, the invention relates to methods for forming linkages by cycloaddition reactions, wherein the method comprises reacting a first alkyl-substituted tetrazine with a first dienophile comprising a irans-cyclooctenyl group followed by reacting a second tetrazine with a second dienophile comprising a cyclooctynyl group, wherein the reaction of the first tetrazine with the first dienophile proceeds in the presence of the second dienophile.

  本发明涉及将四唑与二烯丙基化合物连接的方法，通过至少进行两个环加成反应来建立至少两个连接。这些方法特别适用于建立多重标记策略。具体而言，本发明涉及通过环加成反应形成连接的方法，其中该方法包括将第一个烷基取代的四唑与含有反式环辛烯基团的第一种二烯丙基化合物反应，然后将第二个四唑与含有环辛炔基团的第二种二烯丙基化合物反应，其中第一种四唑与第一种二烯丙基化合物的反应在第二种二烯丙基化合物的存在下进行。
• ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE
  申请人：Behnke Mark L.

  公开号：US20110028478A1

  公开（公告）日：2011-02-03

  The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, R a , R b , R c , and R d are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient. The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.

  本发明提供了式(I)的异噁唑烷FAAH抑制剂或其药学上可接受的形式，其中G、Ra、Rb、Rc和Rd的定义如本文所述。本发明还提供了包括式(I)化合物或其药学上可接受的形式和药学上可接受的赋形剂的制药组合物。本发明还提供了治疗FAAH介导的疾病的方法，包括向需要治疗的患者施用式(I)化合物或其药学上可接受的形式的治疗有效量。